New Journey Health Technology Group Co Ltd

New Journey Health Technology Group Co Ltd has a debt-to-equity ratio of 1.21, indicating a moderate level of leverage, while its current ratio of 0.54 suggests potential liquidity constraints. The company's free cash flow is negative at -123.91 million CNY, and capital expenditure is -257.00 million CNY, reflecting ongoing investment in operations. In terms of profitability, the company's return on equity is 1.58%, and return on assets is 0.47%, both of which are below the typical thresholds for strong performance in the healthcare sector. The net income of 30.94 million CNY is relatively low compared to the company's total assets of 6.65 billion CNY, indicating limited profitability. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, which may increase exposure to regional economic or regulatory risks. The lack of segmental or geographic breakdown in the financial data suggests a need for further transparency. The company's growth trajectory is not clearly defined, as there is no outlook data provided for the current or next fiscal year. However, the negative free cash flow and significant capital expenditure suggest that the company is investing in its operations, which could support future growth. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash is negative after subtracting total debt, which could impact its ability to meet short-term obligations. No dilution sources are identified in the available data, and there is no indication of near-term dilution pressure. Recent events and filings are not detailed in the available data, so no specific recent developments can be reported.